June 15, 2017
Patients does in LEO Pharma’s atopic dermatitis study
LEO Pharma has dosed patients in a phase 3 clinical study of its investigational human monoclonal antibody tralokinumab.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: LEO Pharma
November 3, 2016
LeoPharma and Morphosys join forces to fight skin diseases
LEO Pharma and MorphoSys AG have entered into a strategic alliance for the discovery and development of therapeutic antibodies for the treatment…
July 1, 2016
AstraZeneca, LEO Pharma agree on Trolakinumab global rights deal
AstraZeneca has entered into an agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. As explained by AstraZeneca, Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.
November 26, 2015
LEO Pharma appoints Svend Andersen EVP head of Europe+
LEO Pharma has named Svend Andersen as incoming EVP, Head of Region EUROPE+, who will assume the position of Executive Vice President, Head of Region EUROPE+, on January 1, 2016. He will join LEO Pharma’s Executive Leadership Team and report directly to the CEO.
November 16, 2015
Skin care specialist LEO Pharma acquires Japanese Astellas for € 675 million
LEO Pharma and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for € 675 million.